Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Use of digoxin in heart failure due to systolic dysfunction

Wilson S Colucci, MD
Section Editor
Stephen S Gottlieb, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Digitalis has been used for over 200 years to treat patients with heart failure (HF). Evidence from clinical trials supports the use of digoxin (the most widely used formulation of digitalis) in patients with HF due to left ventricular systolic dysfunction, particularly in patients with more advanced symptoms [1]. However, there is no evidence that digoxin improves survival.

The effects of digoxin on hemodynamics, exercise tolerance, and symptoms in patients with HF and use of digoxin in HF will be reviewed here. The use of digoxin in the management of HF should be considered in the context of comprehensive medical therapy of HF with a reduced LVEF (figure 1) [2]. (See "Overview of the therapy of heart failure with reduced ejection fraction".)


Digitalis acts by inhibiting the Na-K-ATPase pump in myocardial cells [3]. Increased intracellular sodium promotes sodium-calcium exchange, leading to a rise in the intracellular calcium concentration. This results in improved isolated myocyte contractile performance (increased shortening velocity) and overall left ventricular (LV) systolic function [3,4].

Digitalis also exerts an antiadrenergic action in patients with heart failure (HF) by inhibiting sympathetic outflow and augmenting parasympathetic tone. These actions may contribute to the clinical utility of digitalis in some patients.

Digitalis can also be beneficial in patients with HF due to systolic dysfunction with atrial fibrillation (AF) with rapid ventricular response [1], though other agents are preferred for rate control. For patients with compensated systolic HF and AF, a beta blocker (with or without adjunctive digoxin) is generally preferred for rate control. Digitalis slows the ventricular rate during AF, largely via increased parasympathetic tone. Through both rate control and improved contractility, digitalis relieves symptoms of systolic HF when associated with AF and a rapid ventricular rate. (See "Control of ventricular rate in atrial fibrillation: Pharmacologic therapy" and "The management of atrial fibrillation in patients with heart failure".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: Dec 22, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113:2556.
  2. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.
  3. Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.
  4. McMahon WS, Holzgrefe HH, Walker JD, et al. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure. J Am Coll Cardiol 1996; 28:495.
  5. Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987; 9:849.
  6. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13:134.
  7. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56:896.
  8. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303:1443.
  9. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306:699.
  10. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61:371.
  11. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988; 259:539.
  12. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet 1988; 1:489.
  13. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320:677.
  14. Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol 1991; 17:743.
  15. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22:955.
  16. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1.
  17. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525.
  18. Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol 1987; 9 Suppl 2:S61.
  19. Kromer EP, Elsner D, Riegger GA. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. J Cardiovasc Pharmacol 1990; 16:9.
  20. Davies RF, Beanlands DS, Nadeau C, et al. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. J Am Coll Cardiol 1991; 18:1602.
  21. Alicandri C, Fariello R, Boni E, et al. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol 1989; 14 Suppl 8:S77.
  22. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997; 30:42.
  23. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J 1998; 135:389.
  24. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001; 38:806.
  25. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871.
  26. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178.
  27. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403.
  28. Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.
  29. Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 1988; 12:1299.
  30. Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol 1989; 13:1138.
  31. Tanabe Y, Takahashi M, Momotsu T, et al. Effect of digoxin on exercise performance in mildly symptomatic patients with idiopathic dilated cardiomyopathy and sinus rhythm. Jpn Heart J 1994; 35:301.
  32. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.
  33. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI5.
  34. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.
  35. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984; 69:451.
  36. Schobel HP, Oren RM, Roach PJ, et al. Contrasting effects of digitalis and dobutamine on baroreflex sympathetic control in normal humans. Circulation 1991; 84:1118.
  37. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80:65.
  38. Krum H, Bigger JT Jr, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289.
  39. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22:1564.
  40. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002; 39:946.
  41. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.